Search for Clinical Trial Results

Sponsored By

Mantle Cell Lymphoma - 25 Studies Found

Status Study
Active, not recruiting Study Name: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2011-03-24
Interventions:
  • Drug: lenalidomide

Completed Study Name: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2007-12-19
Interventions: Drug: modified Hyper-CVAD rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorub
Completed Study Name: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2007-12-19
Interventions:
  • Drug: Bortezomib Administered

Active, not recruiting Study Name: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Date: 2011-08-16
Interventions:
  • Drug: Rituximab 375 mg/m2 on d
Terminated Study Name: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2009-02-12
Interventions: Drug: P276-00 P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 m
Recruiting Study Name: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2016-07-19
Interventions: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
Active, not recruiting Study Name: Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2012-06-26
Interventions: Drug: Rituximab, Bendamustine, Cytarabine. 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabi
Completed Study Name: Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: MANTLE CELL LYMPHOMA
Date: 2008-11-05
Interventions: Drug: Lenalidomide and Dexametasone Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral ad
Terminated Study Name: Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Date: 2009-02-18
Interventions: Drug: ZARNESTRA (Tipifarnib)
Completed Study Name: Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
Condition: Mantle Cell Lymphoma
Date: 2006-01-31
Interventions:
  • Drug: Adriblastin
  • Drug: dexamethasone
Next >>>